David Bailey Purchases 4,918 Shares of KindlyMD (NASDAQ:NAKA) Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey bought 4,918 shares of KindlyMD stock in a transaction dated Tuesday, August 18th. The stock was acquired at an average cost of $5.12 per share, for a total transaction of $25,180.16. Following the completion of the acquisition, the chief executive officer directly owned 3,180,394 shares in the company, valued at $16,283,617.28. This represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

KindlyMD Trading Up 4.0%

NASDAQ NAKA traded up $0.24 during trading hours on Thursday, reaching $6.30. 306,929 shares of the company’s stock were exchanged, compared to its average volume of 197,571. The firm has a fifty day moving average of $4.45 and a 200-day moving average of $7.29. KindlyMD, Inc. has a one year low of $3.33 and a one year high of $432.40. The stock has a market cap of $112.77 million, a PE ratio of -0.18 and a beta of 15.95.

KindlyMD (NASDAQ:NAKA) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. The business had revenue of $35.87 million during the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. As a group, research analysts forecast that KindlyMD, Inc. will post -16.8 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on NAKA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a report on Friday, August 7th. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Finally, TD Cowen raised their price target on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a report on Monday, July 27th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $22.33.

Hedge Funds Weigh In On KindlyMD

Several large investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. bought a new stake in KindlyMD during the 4th quarter worth about $8,993,000. ParaFi Capital LP acquired a new position in KindlyMD during the 3rd quarter valued at about $443,055,000. Hunting Hill Global Capital LLC bought a new position in shares of KindlyMD in the 4th quarter valued at about $4,672,000. Yorkville Advisors Global LP acquired a new stake in shares of KindlyMD during the 4th quarter worth approximately $3,265,000. Finally, UBS Group AG acquired a new stake in shares of KindlyMD during the 4th quarter worth approximately $2,958,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.